drugset / Trial / NCT05561257

Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster

NCT05561257

Phase 2 Terminated 12 enrolled Pascoe Pharmazeutische Praeparate GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy and tolerability of three different doses of Pascorbin® besides standard medication with placebo and the reduction of herpes zoster-associated clinical symptoms as an add-on therapy for patients suffering from acute herpes zoster in primary care

Timeline

Start
2020-07-20
Primary completion
2024-02-28
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 750 mg
Subject Vitamin C Other / unclassified 7.5 g
Subject Vitamin C Other / unclassified 15 g

Indications